Medical Writers News Hubb
Advertisement Banner
  • Home
  • News
  • Papers
  • Contact
No Result
View All Result
  • Home
  • News
  • Papers
  • Contact
No Result
View All Result
Wellnessnewshubb
No Result
View All Result
Home News

FDA clears device authorized under Safer Technologies Program

admin by admin
March 9, 2023
in News


The FDA cleared a new gastric calibration tube last week, announcing it as the first authorization of a device under the agency’s Safer Technologies Program (STeP).

FDA launched STeP in 2021, modeling the program on its breakthrough devices designation program. STeP covers devices that could improve the safety of treatments or diagnostics. These are aimed at underlying diseases or conditions that are less serious than those treated or diagnosed by devices eligible for breakthrough designation.

Endolumik received FDA 510(k) clearance for its fluorescence-guided gastric calibration tube (FG Bougie). It offers improved visualization during gastric and bariatric surgical procedures. The tube serves as a sizing and measurement guide during gastric resection and facilitates stomach decompression, drainage of gastric fluids, and testing for staple line leaks.

The device emits near-infrared light so the surgeon can see the tube clearly through thick layers of stomach tissue and body fat. Morgantown, West Virginia-based Endolumik said poor visualization can lead to surgical complications such as perforation, excessive gastric sleeve narrowing and inadvertent stapling of the calibration tube.

More about STeP

STeP devices are those that improve on existing diagnostics’ or treatments’ safety by reducing adverse events, device failures, use-related hazards or user errors or by improving the safety of other devices or interventions.

In a news release, the FDA said it intends for the program to offer patients more timely access by expediting product development, assessment and review. However, the FDA says it maintains its standards for safety and effectiveness, data requirements and quality of review.

 



Source link

Previous Post

Breakthrough drug works against all the main types of primary bone cancer

Next Post

Early outpatient treatment of COVID-19 with metformin could reduce the risk of developing long COVID

Next Post

Early outpatient treatment of COVID-19 with metformin could reduce the risk of developing long COVID

Recommended

FDA accelerates medical device approvals

5 months ago

Mayo develops AI childbirth risk prediction tool for women in labor

7 months ago

Future-Proof Your Point of Care Solutions

2 months ago

Metabolomic differences in breast milk throughout lactation

4 weeks ago

Get Health and Medical Consultation

1 month ago

HPV vaccine rates in Utah increase by more than 16% among young men and women, CDC data reveals

5 months ago
Medical-Writers-(-white-)

© Medical Writers News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Papers
  • Contact

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Papers
  • Contact

© 2022 Medical Writers News Hubb All rights reserved.